Online citations, reference lists, and bibliographies.
← Back to Search

Fumaric Acid Esters Exert Neuroprotective Effects In Neuroinflammation Via Activation Of The Nrf2 Antioxidant Pathway.

R. Linker, De-hyung Lee, Sarah Ryan, A. van Dam, R. Conrad, P. Bista, Weike Zeng, Xiaoping Hronowsky, A. Buko, Sowmya Chollate, G. Ellrichmann, W. Brück, K. Dawson, S. Goelz, S. Wiese, R. Scannevin, M. Lukashev, R. Gold
Published 2011 · Medicine, Biology

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
Inflammation and oxidative stress are thought to promote tissue damage in multiple sclerosis. Thus, novel therapeutics enhancing cellular resistance to free radicals could prove useful for multiple sclerosis treatment. BG00012 is an oral formulation of dimethylfumarate. In a phase II multiple sclerosis trial, BG00012 demonstrated beneficial effects on relapse rate and magnetic resonance imaging markers indicative of inflammation as well as axonal destruction. First we have studied effects of dimethylfumarate on the disease course, central nervous system, tissue integrity and the molecular mechanism of action in an animal model of chronic multiple sclerosis: myelin oligodendrocyte glycoprotein induced experimental autoimmune encephalomyelitis in C57BL/6 mice. In the chronic phase of experimental autoimmune encephalomyelitis, preventive or therapeutic application of dimethylfumarate ameliorated the disease course and improved preservation of myelin, axons and neurons. In vitro, the application of fumarates increased murine neuronal survival and protected human or rodent astrocytes against oxidative stress. Application of dimethylfumarate led to stabilization of the transcription factor nuclear factor (erythroid-derived 2)-related factor 2, activation of nuclear factor (erythroid-derived 2)-related factor 2-dependent transcriptional activity and accumulation of NADP(H) quinoline oxidoreductase-1 as a prototypical target gene. Furthermore, the immediate metabolite of dimethylfumarate, monomethylfumarate, leads to direct modification of the inhibitor of nuclear factor (erythroid-derived 2)-related factor 2, Kelch-like ECH-associated protein 1, at cysteine residue 151. In turn, increased levels of nuclear factor (erythroid-derived 2)-related factor 2 and reduced protein nitrosylation were detected in the central nervous sytem of dimethylfumarate-treated mice. Nuclear factor (erythroid-derived 2)-related factor 2 was also upregulated in the spinal cord of autopsy specimens from untreated patients with multiple sclerosis. In dimethylfumarate-treated mice suffering from experimental autoimmune encephalomyelitis, increased immunoreactivity for nuclear factor (erythroid-derived 2)-related factor 2 was detected by confocal microscopy in neurons of the motor cortex and the brainstem as well as in oligodendrocytes and astrocytes. In mice deficient for nuclear factor (erythroid-derived 2)-related factor 2 on the same genetic background, the dimethylfumarate mediated beneficial effects on clinical course, axon preservation and astrocyte activation were almost completely abolished thus proving the functional relevance of this transcription factor for the neuroprotective mechanism of action. We conclude that the ability of dimethylfumarate to activate nuclear factor (erythroid-derived 2)-related factor 2 may offer a novel cytoprotective modality that further augments the natural antioxidant responses in multiple sclerosis tissue and is not yet targeted by other multiple sclerosis therapies.
This paper references
Direct measurement of NAD(P)H:quinone reductase from cells cultured in microtiter wells: a screening assay for anticarcinogenic enzyme inducers.
H. Prochaska (1988)
Selective stimulation of T helper 2 cytokine responses by the anti‐psoriasis agent monomethylfumarate
R. de Jong (1996)
Dimethylfumarate is an inhibitor of cytokine-induced E-selectin, VCAM-1, and ICAM-1 expression in human endothelial cells.
M. Vandermeeren (1997)
An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements.
K. Itoh (1997)
The antipsoriatic agent dimethylfumarate immunomodulates T‐cell cytokine secretion and inhibits cytokines of the psoriatic cytokine network
Ockenfels (1998)
Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study
Mrowietz (1998)
Oligodendrocyte and axon pathology in clinically silent multiple sclerosis lesions
I. Mews (1998)
Activation of Endogenous Antioxidant Defenses in Neuronal Cells Prevents Free Radical‐Mediated Damage
S. Duffy (1998)
Reduction of H2O2-evoked, intracellular calcium increases in the rat N18-RE-105 neuronal cell line by pretreatment with an electrophilic antioxidant inducer
J. Su (1999)
L-Dopa stimulates expression of the antioxidant enzyme NAD(P)H:quinone oxidoreductase (NQO) in cultured astroglial cells.
F. L. van Muiswinkel (2000)
Glutamate excitotoxicity in a model of multiple sclerosis
D. Pitt (2000)
Dimethylfumarate inhibits TNF-induced nuclear entry of NF-kappa B/p65 in human endothelial cells.
R. Loewe (2002)
Axon Loss in the Spinal Cord Determines Permanent Neurological Disability in an Animal Model of Multiple Sclerosis
J. Wujek (2002)
Dimethylfumarate Inhibits TNF-Induced Nuclear Entry of NF-κB/p65 in Human Endothelial Cells1
R. Loewe (2002)
CNTF is a major protective factor in demyelinating CNS disease: A neurotrophic cytokine as modulator in neuroinflammation
R. Linker (2002)
Induction of NAD(P)H quinone: oxidoreductase1 inhibits carcinogen-induced aberrant crypt foci in colons of Sprague-Dawley rats.
A. Begleiter (2003)
Identification of the NF-E2-related Factor-2-dependent Genes Conferring Protection against Oxidative Stress in Primary Cortical Astrocytes Using Oligonucleotide Microarray Analysis*
J. Lee (2003)
Dimethylfumarate is a potent inducer of apoptosis in human T cells.
F. Treumer (2003)
Monomethylfumarate affects polarization of monocyte‐derived dendritic cells resulting in down‐regulated Th1 lymphocyte responses
N. Litjens (2004)
Axonal protection using flecainide in experimental autoimmune encephalomyelitis
D. Bechtold (2004)
Green Tea Epigallocatechin-3-Gallate Mediates T Cellular NF-κB Inhibition and Exerts Neuroprotection in Autoimmune Encephalomyelitis1
O. Aktas (2004)
Nuclear Factor E2-Related Factor 2-Dependent Antioxidant Response Element Activation by tert-Butylhydroquinone and Sulforaphane Occurring Preferentially in Astrocytes Conditions Neurons against Oxidative Insult
A. Kraft (2004)
Induction of the Nrf2-driven Antioxidant Response Confers Neuroprotection during Mitochondrial Stress in Vivo*
A. Shih (2005)
A Small-Molecule-Inducible Nrf2-Mediated Antioxidant Response Provides Effective Prophylaxis against Cerebral Ischemia In Vivo
A. Shih (2005)
The Carboxy-Terminal Neh3 Domain of Nrf2 Is Required for Transcriptional Activation
P. Nioi (2005)
Detoxication enzyme inducers modify cytokine production in rat mixed glial cells
A. Wierinckx (2005)
Neuronal Damage in Autoimmune Neuroinflammation Mediated by the Death Ligand TRAIL
O. Aktas (2005)
Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsis.
R. Thimmulappa (2006)
Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research.
R. Gold (2006)
Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration
S. Schilling (2006)
Activation of the Keap1/Nrf2 pathway for neuroprotection by electrophilic [correction of electrophillic] phase II inducers.
T. Satoh (2006)
Oral fumaric acid esters for the treatment of active multiple sclerosis: an open‐label, baseline‐controlled pilot study
S. Schimrigk (2006)
Reactivity of dimethyl fumarate and methylhydrogen fumarate towards glutathione and N-acetyl-L-cysteine--preparation of S-substituted thiosuccinic acid esters.
T. Schmidt (2007)
A genomic screen for activators of the antioxidant response element
Yanxia Liu (2007)
Vacuolar leukoencephalopathy with widespread astrogliosis in mice lacking transcription factor Nrf2.
A. Hubbs (2007)
Covalent modification at Cys151 dissociates the electrophile sensor Keap1 from the ubiquitin ligase CUL3.
G. Rachakonda (2008)
Pattern of axonal injury in murine myelin oligodendrocyte glycoprotein induced experimental autoimmune encephalomyelitis: Implications for multiple sclerosis
E. Herrero-Herranz (2008)
Fumarates for the treatment of multiple sclerosis: potential mechanisms of action and clinical studies
R. Linker (2008)
Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study
L. Kappos (2008)
Identification and development of new therapeutics for multiple sclerosis.
R. Linker (2008)
Keap1/Nrf2 system regulates neuronal survival as revealed through study of keap1 gene-knockout mice.
T. Satoh (2009)
TASK1 modulates inflammation and neurodegeneration in autoimmune inflammation of the central nervous system.
S. Bittner (2009)
Chitosan prevents oxidative stress-induced amyloid β formation and cytotoxicity in NT2 neurons: involvement of transcription factors Nrf2 and NF-κB
F. Khodagholi (2010)
Neuroprotective Effects of the Triterpenoid, CDDO Methyl Amide, a Potent Inducer of Nrf2-Mediated Transcription
L. Yang (2009)
Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: Critical role for the astrocyte
P. Chen (2009)
Induction of Nrf2 and xCT are involved in the action of the neuroprotective antibiotic ceftriaxone in vitro
J. Lewerenz (2009)
Simple ortho- and para-hydroquinones as compounds neuroprotective against oxidative stress in a manner associated with specific transcriptional activation.
T. Satoh (2009)
Cytoprotective effects of lindenenyl acetate isolated from Lindera strychnifolia on mouse hippocampal HT22 cells.
B. Li (2009)
Sulforaphane protects astrocytes against oxidative stress and delayed death caused by oxygen and glucose deprivation
Camelia A. Danilov (2009)
Isolation and enrichment of embryonic mouse motoneurons from the lumbar spinal cord of individual mouse embryos
S. Wiese (2010)
The absence of the pro-antioxidant transcription factor Nrf2 exacerbates experimental autoimmune encephalomyelitis.
D. Johnson (2010)
Functional role of brain-derived neurotrophic factor in neuroprotective autoimmunity: therapeutic implications in a model of multiple sclerosis.
R. Linker (2010)
Nrf2 and DJ1 are consistently upregulated in inflammatory multiple sclerosis lesions.
J. van Horssen (2010)
Fumaric acid dialkyl esters deprive cultured rat oligodendroglial cells of glutathione and upregulate the expression of heme oxygenase 1
Anette Thiessen (2010)
- derived neurotrophic factor in neuroprotective autoimmunity : therapeutic implications in a model of multiple sclerosis
RA Linker (2010)
Functional role of
RA Linker

This paper is referenced by
Dimethyl Fumarate, an Approved Multiple Sclerosis Treatment, Reduces Brain Oxidative Stress in SIV-Infected Rhesus Macaques: Potential Therapeutic Repurposing for HIV Neuroprotection
Yoelvis Garcia-Mesa (2021)
Effectiveness and safety of dimethyl fumarate in progressive multiple sclerosis
Vanessa F Moreira Ferreira (2021)
Potential therapeutic effects of Nrf2 activators on intracranial hemorrhage
Takahiko Imai (2021)
The Effects of Two Nrf2 Activators, Bardoxolone Methyl and Omaveloxolone, on Retinal Ganglion Cell Survival during Ischemic Optic Neuropathy
Jia-Ying Chien (2021)
Highly Potent and Selective Butyrylcholinesterase Inhibitors for Cognitive Improvement and Neuroprotection.
Qi Li (2021)
Attenuation of High Glucose-Induced Damage in RPE Cells through p38 MAPK Signaling Pathway Inhibition
Grazia Maugeri (2021)
Dimethyl fumarate protects the aged brain following chronic cerebral hypoperfusion-related ischemia in rats in Nrf2-dependent manner.
Seyyedeh-Mahla Shavakandi (2021)
Impaired antioxidant KEAP1-NRF2 system in amyotrophic lateral sclerosis: NRF2 activation as a potential therapeutic strategy
Silvia Bono (2021)
Natural antioxidants for neuroinflammatory disorders and possible involvement of Nrf2 pathway: A review
Sanjiv Singh (2021)
Effectiveness of Dimethyl Fumarate in Real-World Clinical Practice and Strategy to Minimize Adverse Effects and Use of Healthcare Resources
A. Rodríguez-Regal (2021)
Dimethyl fumarate prevents cytotoxicity and apoptosis mediated by oxidative stress in human adipose-derived mesenchymal stem cells.
Shima Shekarchi (2021)
Tissue/Biofluid Specific Molecular Cartography of Leishmania donovani Infected BALB/c Mice: Deciphering Systemic Reprogramming
Sanchita Das (2021)
Emerging Therapeutic Applications for Fumarates.
A. Hoogendoorn (2021)
The Antioxidant Transcription Factor Nrf2 in Cardiac Ischemia–Reperfusion Injury
Extracts from Euphorbia heterophylla naturally grown in Brazil – Chemical constitution and bioactivities
Ueveton Pimentel da Silva (2021)
Hyperhomocysteinemia-induced Nrf2/HO-1 pathway suppression aggravates cardiac remodeling of hypertensive rats.
P. Cao (2021)
The Current Challenges for Drug Discovery in CNS Remyelination
Sonia Balestri (2021)
Sapropterin (BH4) Aggravates Autoimmune Encephalomyelitis in Mice.
K. Schmitz (2021)
Dimethyl fumarate dose-dependently increases mitochondrial gene expression and function in muscle and brain of Friedreich's ataxia model mice.
C. Hui (2021)
Nrf2/HO-1 Signaling Activator Acetyl-11-keto-beta Boswellic Acid (AKBA)-Mediated Neuroprotection in Methyl Mercury-Induced Experimental Model of ALS.
Elizabeth Minj (2021)
Oral dimethyl fumarate induces changes within the peripheral neutrophil compartment of patients with psoriasis that are linked with skin improvement *
P. J. Morrison (2021)
Krebs cycle: activators, inhibitors and their roles in the modulation of carcinogenesis.
Amin Gasmi (2021)
Subconjunctival injections of dimethyl fumarate inhibit lymphangiogenesis and allograft rejection in the rat cornea.
Jianfeng Yu (2021)
Natural products in drug discovery: advances and opportunities
A. Atanasov (2021)
Comparative Efficacy and Safety of Ozanimod and Dimethyl Fumarate for Relapsing-Remitting Multiple Sclerosis Using Matching-Adjusted Indirect Comparison
S. Cohan (2021)
SLC6A14 and SLC38A5 Drive the Glutaminolysis and Serine–Glycine–One-Carbon Pathways in Cancer
Tyler Sniegowski (2021)
Mitochondrial arginase-2 is essential for IL-10 metabolic reprogramming of inflammatory macrophages
J. Dowling (2021)
Anti-Inflammatory and Anti-Oxidant Effect of Dimethyl Fumarate in Cystic Fibrosis Bronchial Epithelial Cells
O. Laselva (2021)
SARS-CoV-2 Infection and Oral Health: Therapeutic Opportunities and Challenges
Christopher J. Coke (2021)
The Nrf2 Pathway in Ischemic Stroke: A Review
M. Farina (2021)
Drug targeting to sites of oxidative stress using the Baeyer-Villiger reaction
T. Avery (2021)
See more
Semantic Scholar Logo Some data provided by SemanticScholar